# 68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer

> **NCT04216134** · PHASE1 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 19 (actual)

## Conditions studied

- Biochemically Recurrent Prostate Carcinoma

## Interventions

- **DRUG:** Gallium Ga 68-labeled PSMA-11
- **PROCEDURE:** Positron Emission Tomography

## Key facts

- **NCT ID:** NCT04216134
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-12
- **Primary completion:** 2022-12-09
- **Final completion:** 2022-12-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-06-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04216134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04216134, "68Ga-PSMA-11 PET for the Diagnosis of Biochemically Recurrent Prostate Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04216134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*